Melflufen: An Anticancer Drug Under Development by Oncopeptides AB – Global Emerging Insight and Market Forecasts 2020-2030 – ResearchAndMarkets.com

Melflufen: An Anticancer Drug Under Development by Oncopeptides AB – Global Emerging Insight and Market Forecasts 2020-2030 – ResearchAndMarkets.com




Melflufen: An Anticancer Drug Under Development by Oncopeptides AB – Global Emerging Insight and Market Forecasts 2020-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “MELFLUFEN – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.

“MELFLUFEN- Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for AL Amyloidosis in 7 Major Markets. A detailed picture of the MELFLUFEN in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview

Melflufen is an anticancer drug under development by Oncopeptides AB. It is a peptidase enhanced cytotoxic that exerts a targeted delivery of melphalan in cells with high expression of aminopeptidases, such as aminopeptidase N, which has been described as over-expressed in human malignancies.

Scope of the Report

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around MELFLUFEN.
  • The report contains forecasted sales for MELFLUFEN till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for AL Amyloidosis.
  • The report also features the SWOT analysis with analyst insights and key findings of MELFLUFEN.

MELFLUFEN Analytical Perspective

In-depth MELFLUFEN Market Assessment

This report provides a detailed market assessment of MELFLUFEN in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

MELFLUFEN Clinical Assessment

The report provides the clinical trials information of MELFLUFEN covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

  • In the coming years, the market scenario for AL Amyloidosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence MELFLUFEN dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for AL Amyloidosis are giving market competition to MELFLUFEN and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of MELFLUFEN.
  • The in-depth analysis of the forecasted sales data of MELFLUFEN from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MELFLUFEN.

Key Questions Answered

  • Which company is developing MELFLUFEN along with the phase of the clinical study?
  • What is the technology utilized in the development of MELFLUFEN?
  • What is the product type, route of administration and mechanism of action of MELFLUFEN?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MELFLUFEN development?
  • What are the key designations that have been granted to MELFLUFEN?
  • What is the forecasted market scenario of MELFLUFEN?
  • What is the history of MELFLUFEN and what is its future?
  • What is the forecasted sales of MELFLUFEN in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to MELFLUFEN?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Key Topics Covered:

1. Drug Overview

1.1. Product Detail

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4. Research and development activity

1.4.1. Clinical Development

1.4.2. Safety and Efficacy

1.5. Other Development Activities

2. Market Assessment

2.1. 7MM Market Analysis

2.2. The United States Market

2.3. Germany Market

2.4. France Market

2.5. Italy Market

2.6. Spain Market

2.7. United Kingdom Market

2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/k5sxdy

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900